Corline Biomedical AB
Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications in Sweden. The company's products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used in surgery as an anticoagulant pharmaceutical compound to prevent harmful blood clotting. Its products … Read more
Corline Biomedical AB - Asset Resilience Ratio
Corline Biomedical AB (CLBIO) has an Asset Resilience Ratio of 7.07% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Corline Biomedical AB's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Corline Biomedical AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr5.82 Million | 7.07% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr5.82 Million | 7.07% |
Asset Resilience Insights
- Limited Liquidity: Corline Biomedical AB maintains only 7.07% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Corline Biomedical AB Industry Peers by Asset Resilience Ratio
Compare Corline Biomedical AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Corline Biomedical AB (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Corline Biomedical AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 18.64% | Skr17.67 Million | Skr94.76 Million | +1.65pp |
| 2023-12-31 | 16.99% | Skr17.01 Million | Skr100.11 Million | -8.76pp |
| 2022-12-31 | 25.75% | Skr26.21 Million | Skr101.78 Million | -15.20pp |
| 2021-12-31 | 40.95% | Skr41.63 Million | Skr101.66 Million | +26.09pp |
| 2020-12-31 | 14.86% | Skr8.66 Million | Skr58.28 Million | -20.99pp |
| 2019-12-31 | 35.85% | Skr22.86 Million | Skr63.75 Million | -8.09pp |
| 2018-12-31 | 43.94% | Skr27.64 Million | Skr62.91 Million | +11.16pp |
| 2017-12-31 | 32.78% | Skr16.86 Million | Skr51.43 Million | +4.03pp |
| 2016-12-31 | 28.74% | Skr11.86 Million | Skr41.27 Million | -- |